Press release
Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Respiratory Syncytial Virus Pipeline. Dive into DelveInsight's comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from Respiratory Syncytial Virus Pipeline Report
* On 19 August 2025, ModernaTX Inc . announced a study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months.
* On 17 August 2025, Shenzhen Shenxin Biotechnology Co., Lt d conducted a study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.
* On 14 August 2025, Pfizer conducted a phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
* DelveInsight's Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
* The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
* Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
Stay ahead with the most recent pipeline outlook for Respiratory Syncytial Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Respiratory Syncytial Virus Emerging Drugs Profile
* Clesrovimab: Merck Sharp & Dohme
Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
* IVX A12: AstraZeneca
IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults greater than or equal to 60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax's RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
* MV-012-968: Meissa Vaccines, Inc
MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naive children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company's proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
The Respiratory Syncytial Virus Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
* Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market
Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline. Access DelveInsight's detailed report now! @ New Respiratory Syncytial Virus Drugs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Respiratory Syncytial Virus Companies
AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Respiratory Syncytial Virus Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Unveil the future of Respiratory Syncytial Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Respiratory Syncytial Virus Pipeline Report
* Coverage- Global
* Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
* Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
* Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Respiratory Syncytial Virus Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Respiratory Syncytial Virus (RSV): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Respiratory Syncytial Virus (RSV) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Respiratory Syncytial Virus (RSV) Collaboration Deals
* Late Stage Products (Phase III)
* Clesrovimab: Merck Sharp & Dohme
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IVX A12: AstraZeneca
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MV-012-968: Meissa Vaccines, Inc
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Respiratory Syncytial Virus (RSV) Key Companies
* Respiratory Syncytial Virus (RSV) Key Products
* Respiratory Syncytial Virus (RSV)- Unmet Needs
* Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
* Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
* Respiratory Syncytial Virus (RSV) Analyst Views
* Respiratory Syncytial Virus (RSV) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=respiratory-syncytial-virus-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4155039 • Views: …
More Releases from ABNewswire
Mild Cognitive Impairment Market: Epidemiology, Therapies, Companies Working, De …
The Mild Cognitive Impairment market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Mild Cognitive Impairment market size from 2020 to 2034.
Emerging therapies for Mild Cognitive Impairment, including LEQEMBI (lecanemab), KISUNLA (donanemab), and others, are anticipated to drive growth in the Mild Cognitive Impairment market in the coming years.
DelveInsight has launched a new report on "Mild Cognitive Impairment - Market…
Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approva …
DelveInsight's, "Spasticity Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in…
Experia Moving Expands Premium Moving Services to Greenwich, CT With Elite Team …
Experia Moving, known for elite relocation services in NYC, is now serving Greenwich, CT. With professionally trained crews, premium packing materials, and live truck tracking, Experia brings a VIP moving experience to families and businesses in Fairfield County.
Greenwich, CT - Aug 21, 2025 - Experia Moving, a trusted name in luxury relocation services in New York City, is proud to announce the expansion of its elite moving solutions to Greenwich,…
JAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Appr …
DelveInsight's, "JAK Inhibitor Pipeline Insight" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in JAK Inhibitor pipeline landscape. It covers the JAK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitor therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive JAK Inhibitor pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
